Velpatasvir Powder CAS 1377049-84-7 Purity Velpatasvir Powder API Velpatasvir

• Customization: Available
• Powder: Yes
• Customized: Customized
• Certification: GMP, ISO 9001, USP, BP
• Suitable for: Adult
• State: Powder
• Purity: >98%
• Sample: Available
• OEM: Available
• MOQ: 1kg
• Keyword 1: Velpatasvir
• Keyword 2: Velpatasvir Powder
• Storage: Dry and Cool Place
• Transport Package: Foil Bag/25kg Drum
• Specification: 98%
• Trademark: /
• Origin: China
• Production Capacity: 10000

Product Description

Description
Velpatasvir is an NS5A inhibitor (by Gilead) which is used together with sofosbuvir in the treatment of hepatitis C infection of all six major genotypes.
Velpatasvir is a small molecule direct-acting antiviral used in the treatment of hepatitis C in combination with sofosbuvir. Velpatasvir prevents viral replication by inhibiting non-structural protein 5A (NS5A).

Name	Velpatasvir
Grade	Pharmaceutical Grade
Appearance	White powder
Specification	98%

Function and Application
Velpatasvir is innovated by Gilead to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Velpatasvir is a Direct-Acting Antiviral (DAA) medication used together with Sofosbuvir. The mechanism of action is as a Breast Cancer Resistance Protein Inhibitor, and P-Glycoprotein Inhibitor, and Organic Anion Transporting Polypeptide 1B1 Inhibitor, and Organic Anion Transporting Polypeptide 1B3 Inhibitor, and Organic Anion Transporting Polypeptide 2B1 Inhibitor. It blocks NS5A, a protein necessary for hepatitis C virus replication assembly.